GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (OTCPK:DSNKY) » Definitions » EBITDA Margin %

Daiichinkyo Co (Daiichinkyo Co) EBITDA Margin % : 10.08% (As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Daiichinkyo Co EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Daiichinkyo Co's EBITDA for the three months ended in Mar. 2024 was $288 Mil. Daiichinkyo Co's Revenue for the three months ended in Mar. 2024 was $2,860 Mil. Therefore, Daiichinkyo Co's EBITDA margin for the quarter that ended in Mar. 2024 was 10.08%.

Daiichinkyo Co EBITDA Margin % Historical Data

The historical data trend for Daiichinkyo Co's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co EBITDA Margin % Chart

Daiichinkyo Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.53 13.95 13.16 15.89 18.91

Daiichinkyo Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.29 19.11 18.72 27.80 10.08

Competitive Comparison of Daiichinkyo Co's EBITDA Margin %

For the Drug Manufacturers - General subindustry, Daiichinkyo Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Daiichinkyo Co's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Daiichinkyo Co's EBITDA Margin % falls into.


Daiichinkyo Co EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Daiichinkyo Co's EBITDA Margin % for the fiscal year that ended in Mar. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Mar. 2024 )/Revenue (A: Mar. 2024 )
=2021.818/10690.849
=18.91 %

Daiichinkyo Co's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=288.322/2859.585
=10.08 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Daiichinkyo Co  (OTCPK:DSNKY) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Daiichinkyo Co EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Daiichinkyo Co (Daiichinkyo Co) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (OTCPK:DSNKY) » Definitions » EBITDA Margin %
Comparable Companies
TSE:4519 TSE:4503 TSE:4578 TSE:4151 TSE:4528 TSE:4536 TSE:4552 TSE:4882 LLY JNJ MRK ABBV XSWX:ROG LSE:AZN XSWX:NOVN PFE AMGN XPAR:SAN BMY GILD
Traded in Other Exchanges
DSKYF:USA 4568:Japan D4S:Germany
Address
3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426
Website
https://www.daiichisankyo.com
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.